Immix Biopharma to present NXC-201 trial data from 45 patients at ASH 2026
IMMX•Immix Biopharma will present interim results from its 45-patient NEXICART-2 trial of NXC-201 at the American Society of Hematology meeting on December 14, 2026.
1. Trial results presentation
Immix Biopharma will present interim results from NEXICART-2, a 45-patient study evaluating the safety and efficacy of NXC-201 in the first U.S. CAR-T trial for relapsed or refractory AL amyloidosis. The results were selected for an oral presentation scheduled for 11:15 a.m. Central Time in New Orleans.
